Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BD Manufacturing Realignment To Affect Up To 1,000 Employees

This article was originally published in The Gray Sheet

Executive Summary

Restructuring plans announced by Becton Dickinson May 19 are expected to include the realignment of certain manufacturing operations and layoffs or reassignment of 500 to 1,000 manufacturing personnel, the company says.

You may also be interested in...



BD Eliminates Distributor Incentives, 1,000 Jobs In Restructuring Initiative

Becton Dickinson's plan to eliminate certain distributor incentive programs that create unpredictability and inefficiency in inventory management will cost the firm about $50 mil. in FY 2000 fourth-quarter revenues and cut earnings by six cents per share, the company announced Sept. 26.

Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT010075

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel